Confirmed 2020 Partners:
Program Partner: BPM
Bio Preventive Medicine Corporation (BPM) is a clinical-staged biotech company. BPM has been focused on translating validated and IP-protected biomarkers into diagnostic solutions for unmet clinical needs, especially in DKD and non-proteinuric renal disease. Our first product, DNlite, is a non-invasive urinary test for predicting/monitoring the progression of Diabetic Kidney Disease (DKD). We can help partners in the development of drugs not only for evaluating renal efficacy but also renal safety.
Exhibition Partner: Frenova
Frenova is the world’s only drug and medical device contract clinical development services provider dedicated exclusively to renal research and its adjacent conditions. As a Fresenius Medical Care North America company, Frenova manages clinical research assets and resources including over 450 principal investigators at more than 260 sites representing 160 medical practices. Frenova’s F1RST Up® network of select investigative sites provides sponsors with accelerated study startup, while Frenova’s SMO manages clinical research staff and streamlines trial operations to help investigators enroll more patients and perform more studies.
Exhibition Partner: Gubra
Gubra is a privately held biotech located in Denmark delivering scientific counselling, contract research services, and projects for co-development in five main areas: Obesity, diabetes, NASH, kidney, and heart diseases. Gubra experts cover pre-clinical disciplines such as in vivo pharmacology, peptide chemistry, molecular pharmacology, histology, 3D imaging, stereology, NGS, bioinformatics and ex vivo assays. Gubra has a hybrid business model with a pipeline of early target and drug discovery programs aimed for partnering while also delivering preclinical services to customers.
Exhibition Partner: EVOTEC
Evotec is a Drug Discovery Alliance and Development Partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide and our more than 3,400 employees provide the highest quality stand-alone and integrated drug discovery and development solutions from target to clinic. For additional information, please go to www.evotec.com and follow us on Twitter @Evotec.
Spotlight Partner: Nordic Bioscience
Nordic Bioscience has more than 25 years’ experience in biomarker development and integrating these biomarkers into clinical trials with extensive scientific expertise in the fields of fibrosis, rheumatology, immunology and oncology.
Using our unique biomarker technology, we identify predictive and prognostic biomarkers which are used to enrich clinical trials and may reduce trial length and size required to determine therapeutic efficacy.
With over 500 publications in leading journals, we pride ourselves with our highly scientific approach and mindset.
Event Partner: DiscoveryBioMed
DiscoveryBioMed, Inc. (DBM) is a boutique R&D and CRO biotechnology company that leverages human cell platform technologies for drug discovery and validation in renal, respiratory, and metabolic therapeutic areas. DBM currently offers highly advanced 3D human cell based in vitro cyst forming models of Polycystic Kidney Disease (PKD) with development underway for a similar system for Chronic Kidney Disease (CKD). To learn more, visit our website or contact MRedmann@DiscoveryBioMed.com for inquiries about available services.
Innovation Partner: NIPOKA
NIPOKA was found as a spin-off from the University Medicine and University Greifswald (Germany). The team has over 20 years of expertise in podocyte research. NIPOKA offers a revolutionary procedure, that enables to determine the exact foot process morphology in biopsies and kidney sections of mice and rats. We can reliably identify foot process effacement without bias in a short time. The procedure is based on super-resolution microscopy and does not require electron microscopy.